Wolverine Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Wolverine Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.81M	Buy	125,265 +100,949	+415%	+$1.45M	0.02%	602
2025 Q4	$346K	Buy	+24,316	New	+$239K	﹤0.01%	1009
2020 Q1	–	Sell	-3,951	Closed	-$38K	–	1517
2019 Q4	$38K	Hold	3,951	–	–	﹤0.01%	1195
2019 Q3	$31K	Hold	3,951	–	–	﹤0.01%	1256
2019 Q2	$49K	Buy	+3,951	New	+$50.1K	﹤0.01%	1203
2014 Q1	–	Sell	-37,000	Closed	-$86K	–	2559
2013 Q4	$86K	Buy	+37,000	New	+$81.2K	﹤0.01%	1513

Other funds holding FOLD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Wolverine Asset Management's FOLD Position: Q1 2026 in Review

Wolverine Asset Management increased its Amicus Therapeutics (FOLD) stake by 415% in Q1 2026, buying an estimated $1.45M and bringing the position to 125,265 shares worth $1.81M. The position accounts for 0.02% of the portfolio, ranked #602.

Wolverine Asset Management first reported a position in FOLD in Q4 2013 and has held it in 6 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Wolverine Asset Management held 125,265 shares of Amicus Therapeutics worth $1.81M as of Q1 2026.
Wolverine Asset Management bought 100,949 Amicus Therapeutics shares in Q1 2026, an estimated $1.45M.
Amicus Therapeutics made up 0.02% of Wolverine Asset Management's portfolio in Q1 2026, its #602 holding.
Wolverine Asset Management first reported a position in Amicus Therapeutics in Q4 2013 and has held it in 6 quarters since.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.